Brief: Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For Cdi At The 16Th Biennial Congress Of The Anaerobe Society Of America
02/08/2022 14:13
Aug 2 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES NEW DATA PRESENTATIONS FROM ONGOING PH2
CLINICAL
TRIAL PROGRAM OF IBEZAPOLSTAT FOR CDI AT THE 16TH BIENNIAL
CONGRESS OF THE ANAEROBE SOCIETY OF AMERICA
Source text for Eikon: ID:nPn1YQn3Sa
Further company coverage: ACXP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln